Related Experiment Video
Updated: Feb 17, 2026

07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
24.4K
Is testing for postprandial hyperinsulinemic hypoglycemia after gastric bypass necessary?
Michèle Gasser1, Claudia Meier1, Sylvia Herren1
1European Center of Excellence for Bariatric and Metabolic Surgery, Bern, Switzerland.
Clinical Nutrition (Edinburgh, Scotland)
|December 7, 2017
Summary
Postprandial hyperinsulinemic hypoglycemia (pHH) after gastric bypass is common. Screening is recommended, as asymptomatic cases pose a significant risk for dangerous hypoglycemia.
Area of Science:
- Bariatric Surgery
- Endocrinology
- Gastroenterology
Background:
- Postprandial hyperinsulinemic hypoglycemia (pHH) is a recognized complication following Roux-en-Y gastric bypass (RYGB).
- pHH can lead to severe, unpredictable hypoglycemic episodes, posing a risk of life-threatening emergencies.
- Early detection of patients at risk for pHH is crucial for effective management.
Purpose of the Study:
- To determine the frequency of pHH in patients after RYGB.
- To identify the occurrence of pHH with or without associated symptoms.
- To evaluate the utility of challenge testing in detecting at-risk individuals.
Main Methods:
- An observational cohort study involving patients approximately one year after RYGB.
- Standardized oral glucose challenge tests with a carbohydrate-rich meal.
- Monitoring of plasma glucose and insulin levels at timed intervals post-meal.
- Symptom classification and further testing with a protein-rich meal for hypoglycemic patients.
Main Results:
- 11.5% of patients developed pHH after a carbohydrate-rich meal.
- 5.3% of patients experienced asymptomatic hypoglycemia.
- Asymptomatic patients demonstrated a statistically significant increased risk for pHH (p=0.008).
- One patient required emergency treatment due to sudden loss of consciousness.
Conclusions:
- The incidence of pHH after RYGB is substantial, with a notable proportion of asymptomatic cases.
- Screening for pHH in post-RYGB patients is warranted.
- Advising at-risk patients to avoid carbohydrate-rich meals is essential for risk management.
Related Concept Videos
Hypoglycemia and Glucagon
1.0K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.0K
Insulin: Dosing Regimen and Adverse Effects
864
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
864
SBAR II: Application of SBAR
6.2K
SBAR is an effective communication tool used by healthcare professionals to communicate patient information accurately. SBAR stands for Situation, Background, Assessment, and Recommendation. For a better understanding, an example is given below.
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
SBAR Report from a Nurse to a Health Care Provider
S: "Hello, Dr. Smith. This is Jane, RN, from the Med Surg unit. I am calling to tell you about Ms. White in Room 210, who is experiencing increased pain and redness at her incision site. Her recent...
6.2K
Oral Hypoglycemic Agents: Glinides
705
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
705
Diabetes Mellitus: Type 2 and Gestational
5.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.1K
Glucagon-like Receptor Agonists
1.0K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K

